share_log

Recursion Pharmaceuticals | DEF 14A: Definitive information statements

Recursion Pharmaceuticals | DEF 14A: Definitive information statements

Recursion Pharmaceuticals | DEF 14A：股東委託書決議
美股sec公告 ·  04/24 05:21
牛牛AI助理已提取核心訊息
Recursion Pharmaceuticals, Inc. (Recursion) filed its definitive proxy statement with the SEC, detailing its upcoming Annual Meeting of Stockholders to be held virtually on June 3, 2024. The proxy statement includes proposals for the election of three Class III directors, Blake Borgeson, R. Martin Chavez, and Dean Y. Li, whose terms are set to expire at the meeting. The statement also addresses executive compensation, with a recommendation for stockholders to approve the compensation of Named Executive Officers. The report highlights key achievements in 2023, such as clinical program advancements, significant partnerships, and the development of the Recursion OS platform. Additionally, the proxy statement outlines the company's executive compensation philosophy, emphasizing a pay-for-performance culture and alignment with stockholder interests. The company's financial performance, including a net loss for the year, is also discussed. The proxy statement includes information on the ownership of Recursion's common stock by certain beneficial owners and management, as well as potential payments upon termination or change in control for executive officers.
Recursion Pharmaceuticals, Inc. (Recursion) filed its definitive proxy statement with the SEC, detailing its upcoming Annual Meeting of Stockholders to be held virtually on June 3, 2024. The proxy statement includes proposals for the election of three Class III directors, Blake Borgeson, R. Martin Chavez, and Dean Y. Li, whose terms are set to expire at the meeting. The statement also addresses executive compensation, with a recommendation for stockholders to approve the compensation of Named Executive Officers. The report highlights key achievements in 2023, such as clinical program advancements, significant partnerships, and the development of the Recursion OS platform. Additionally, the proxy statement outlines the company's executive compensation philosophy, emphasizing a pay-for-performance culture and alignment with stockholder interests. The company's financial performance, including a net loss for the year, is also discussed. The proxy statement includes information on the ownership of Recursion's common stock by certain beneficial owners and management, as well as potential payments upon termination or change in control for executive officers.
Recursion Pharmicals, Inc.（Recursion）向美國證券交易委員會提交了最終委託書，詳細說明了其即將於2024年6月3日虛擬舉行的年度股東大會。委託書包括選舉三名三類董事的提案，即布萊克·博格森、馬丁·查韋斯和李院長，他們的任期將在會議上屆滿。該聲明還涉及高管薪酬，並建議股東批准指定執行官的薪酬。該報告重點介紹了2023年的主要成就，例如臨床項目的進展、重要的合作伙伴關係以及Recursion OS平台的開發。此外，委託書概述了公司的高管薪酬理念，強調了績效薪酬文化和與股東利益的一致性。還討論了該公司的財務業績，包括該年度的淨虧損。委託書包括有關某些受益所有人和管理層對Recursion普通股的所有權的信息，以及執行官在解僱或控制權變更時可能支付的款項的信息。
Recursion Pharmicals, Inc.（Recursion）向美國證券交易委員會提交了最終委託書，詳細說明了其即將於2024年6月3日虛擬舉行的年度股東大會。委託書包括選舉三名三類董事的提案，即布萊克·博格森、馬丁·查韋斯和李院長，他們的任期將在會議上屆滿。該聲明還涉及高管薪酬，並建議股東批准指定執行官的薪酬。該報告重點介紹了2023年的主要成就，例如臨床項目的進展、重要的合作伙伴關係以及Recursion OS平台的開發。此外，委託書概述了公司的高管薪酬理念，強調了績效薪酬文化和與股東利益的一致性。還討論了該公司的財務業績，包括該年度的淨虧損。委託書包括有關某些受益所有人和管理層對Recursion普通股的所有權的信息，以及執行官在解僱或控制權變更時可能支付的款項的信息。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。